Pancreatic ductal adenocarcinoma (PDAC) is characterized by a severe fibrotic component that compromises treatment, alters the immune cell profile and contributes to patient mortality. It has been shown that early on in this process, dynamic changes in tissue biomechanics play an integral role in supporting pancreatic cancer development and progression. Despite the acknowledgement of its importance, a granular view of how stromal composition changes during the course of PDAC progression remains largely unknown. To mimic the quasi-mesenchymal phenotype and pronounced desmoplastic response observed clinically, we utilized a genetically engineered mouse model of PDAC that is driven by a KrasG12D mutation and loss of Tgfbr2 expression. Applicat...
Pancreatic ductal adenocarcinoma (PDA) is an extremely metastatic and lethal disease. Here, in both ...
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers with a 5-years s...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of approximately 10% and is ex...
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality worldwide. Non-specif...
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality worldwide. Non-specif...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with high morbidity and mo...
Many cancer studies now recognize that disease initiation, progression, and response to treatment ar...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer-related death, an...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer-related death, an...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an overall 5-year survival rat...
Pancreatic ductal adenocarcinoma (PDAC) has prominent extracellular matrix (ECM) that compromises tr...
The genetic paradigm of cancer, focused largely on sequential molecular aberrations and associated b...
A well-known feature of human pancreatic ductal adenocarcinoma (PDAC) is the extensive proliferation...
Despite improvements in the understanding of disease biology, pancreatic ductal adenocarcinoma (PDAC...
Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibroblast-rich...
Pancreatic ductal adenocarcinoma (PDA) is an extremely metastatic and lethal disease. Here, in both ...
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers with a 5-years s...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of approximately 10% and is ex...
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality worldwide. Non-specif...
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality worldwide. Non-specif...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with high morbidity and mo...
Many cancer studies now recognize that disease initiation, progression, and response to treatment ar...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer-related death, an...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer-related death, an...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an overall 5-year survival rat...
Pancreatic ductal adenocarcinoma (PDAC) has prominent extracellular matrix (ECM) that compromises tr...
The genetic paradigm of cancer, focused largely on sequential molecular aberrations and associated b...
A well-known feature of human pancreatic ductal adenocarcinoma (PDAC) is the extensive proliferation...
Despite improvements in the understanding of disease biology, pancreatic ductal adenocarcinoma (PDAC...
Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibroblast-rich...
Pancreatic ductal adenocarcinoma (PDA) is an extremely metastatic and lethal disease. Here, in both ...
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers with a 5-years s...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of approximately 10% and is ex...